Evidence map›Paper›PMID 25803700›Full record

ArticlePloS one2015

Endocytosis of a functionally enhanced GFP-tagged transferrin receptor in CHO cells.

Qi He, Xiaoxu Sun, Chong Chu, Qing Jiang, Huifen Zhu, Yong He, Tingting Yue, Ruibo Wang, Ping Lei, Guanxin Shen

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Qi HeDepartment of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Xiaoxu SunDepartment of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Department of Clinical Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Chong ChuDepartment of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Qing JiangDepartment of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Huifen ZhuDepartment of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Yong HeDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Province Key Laboratory of Molecular Imaging, Wuhan, Hubei, China.
Tingting YueBeijing Pushikang Pharmaceutical Technology Co., Ltd, Beijing, China.
Ruibo WangBeijing Pushikang Pharmaceutical Technology Co., Ltd, Beijing, China.
Ping LeiDepartment of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Guanxin ShenDepartment of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Huazhong University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The endocytosis of transferrin receptor (TfR) has served as a model to study the receptor-targeted cargo delivery system for cancer therapy for many years. To accurately evaluate and optically measure this TfR targeting delivery in vitro, a CHO cell line with enhanced green fluorescent protein (EGFP)-tagged human TfR was established. A chimera of the hTfR and EGFP was engineered by fusing EGFP to the amino terminus of hTfR. Data were provided to demonstrate that hTfR-EGFP chimera was predominantly localized on the plasma membrane with some intracellular fluorescent structures on CHO cells and the EGFP moiety did not affect the endocytosis property of hTfR. Receptor internalization occurred similarly to that of HepG2 cells expressing wild-type hTfR. The internalization percentage of this chimeric receptor was about 81 ± 3% of wild type. Time-dependent co-localization of hTfR-EGFP and PE-conjugated anti-hTfR mAb in living cells demonstrated the trafficking of mAb-receptor complexes through the endosomes followed by segregation of part of the mAb and receptor at the late stages of endocytosis. The CHO-hTfR cells preferentially took up anti-hTfR mAb conjugated nanoparticles. This CHO-hTfR cell line makes it feasible for accurate evaluation and visualization of intracellular trafficking of therapeutic agents conjugated with transferrin or Abs targeting the hTfRs.

Indexed as

AnimalsAntibodies, MonoclonalBlotting, WesternCHO CellsCricetinaeCricetulusDNA PrimersEndocytosisFlow CytometryFluorescent Antibody TechniqueGreen Fluorescent ProteinsHumansImmunohistochemistryNanoparticlesPlasmidsReceptors, TransferrinAntibodies, MonoclonalDNA Primersenhanced green fluorescent proteinGreen Fluorescent ProteinsReceptors, TransferrinRecombinant Fusion Proteins

Identifiers

PMID25803700
PMCPMC4372551
OpenAlexW2043883525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.